Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAX 323 (EORTC 24971): TPF vs PF in Head and Neck Cancer
NCT00003888Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 1999
- Primary completion
- Mar 2002
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of docetaxel in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-Free Survival. Started Apr 1999; status: completed.
02
Drugs
docetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00003888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003888.